Current Report Filing (8-k)
August 29 2019 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: August 23, 2019
(Date of earliest event reported)
ImmuCell Corporation
(Exact name of registrant as specified in its charter)
|
DE
|
|
001-12934
|
|
01-0382980
|
|
(State or other jurisdiction
|
|
(Commission File
|
|
(IRS Employer
|
|
of incorporation)
|
|
Number)
|
|
Identification Number)
|
|
56 Evergreen Drive
|
|
|
|
Portland, Maine
|
|
04103
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
207-878-2770
(Registrant's telephone number, including area code)
Not
Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act: None
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events
On August 29, 2019 ImmuCell Corporation (the
"Company") issued a press release announcing that it has received a response from the U.S. Food and Drug Administration
(FDA) to its first phased Nisin Drug Substance submission of the Chemistry, Manufacturing and Controls (CMC) Technical Section
for Re-Tain™, the Company’s novel treatment in development for subclinical mastitis in lactating dairy cows.
The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report
on Form 8-K.
The information shall not be deemed "filed"
for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange
Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
IMMUCELL CORPORATION
|
|
|
|
|
Date: August 29, 2019
|
By:
|
/s/ Michael F. Brigham
|
|
|
|
Michael F. Brigham
|
|
|
|
President, Chief Executive Officer and Principal Financial Officer
|
Exhibit Index
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Apr 2023 to Apr 2024
